25 avril 2023 : BioPharma Reporter - FDA lifts 18-month clinical hold on MaaT Pharma's microbiome therapeutic (English only)

Previous Post28 avril 2023 : Microbiome Post - MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease (English only)
Next Post24 avril 2023 : Endpoints News - FDA lifts nearly two-year hold on MaaT Pharma's microbiome therapy, opens door to PhIII (English only)

25 avril 2023 : BioPharma Reporter – FDA lifts 18-month clinical hold on MaaT Pharma’s microbiome therapeutic (English only)